In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci [PDF]
PeerJ, 2021 Vancomycin-resistant enterococci (VRE) are a serious public health threat and a leading cause of healthcare-associated infections. Bacterial resistance to antibiotics recommended for the treatment of enterococcal infections complicates the management of ...
Nader S. Abutaleb +3 more
doaj +3 more sources
Acute serous and hemorrhagic choroidal effusion associated with topical dorzolamide therapy
American Journal of Ophthalmology Case Reports, 2023 Purpose: To report a case of acute onset unilateral hemorrhagic and serous choroidal effusion associated with dorzolamide administration and antiplatelet use that recurred in a patient who experienced a dorzolamide-induced choroidal effusion ten years ...
Abdulla Shaheen +5 more
doaj +2 more sources
Pharmaceuticals, 2022 To compare the efficacy, patient-reported satisfaction, and safety of preservative-free (PF)-tafluprost, PF-dorzolamide/timolol and preservative-containing (P)-latanoprost in Korean glaucoma patients with ocular surface disease (OSD).
Sang-Woo Park +2 more
doaj +2 more sources
Journal of Medical Case Reports, 2021 Background Cystoid macular edema is a rare, vision-threatening side effect of the taxane family of anticancer agents. There is no established treatment or standard treatment protocol for taxane-related cystoid macular edema.
Mitsuru Otsubo +3 more
doaj +2 more sources
Indian Journal of Ophthalmology, 2022 Purpose: Impaired ocular blood flow is an important risk factor in the pathogenesis of open-angle glaucoma (OAG). Studies have reported that dorzolamide 2% may be effective in improving ocular blood flow (OBF) in OAG patients. The objective of this study
Pratheeba D Nivean +5 more
doaj +2 more sources
Dramatic response to topical dorzolamide in X-linked retinoschisis
Indian Journal of Ophthalmology, 2020 Macular involvement is commonly seen in cases with X-linked retinoschisis (XLRS) which includes foveal schisis and cystic maculopathy. Although no definitive treatment has been described, the use of topical 2% dorzolamide hydrochloride in such cases has ...
Rajeswari Thangavel +3 more
doaj +2 more sources
Advances in dorzolamide hydrochloride delivery: harnessing nanotechnology for enhanced ocular drug delivery in glaucoma management. [PDF]
Discov NanoDorzolamide hydrochloride (DRZ) is a carbonic anhydrase inhibitor utilized in managing elevated intraocular pressure (IOP) associated with glaucoma. However, its clinical effectiveness is hindered by a short half-life, low residence time, and the need ...
Pardeshi SR +5 more
europepmc +2 more sources
Efficacy and Safety of a Fixed-Dose Combination of Brinzolamide 1%/Timolol 0.5% vs. Dorzolamide 2%/Timolol 0.5% in Indian Patients With Primary Open-Angle Glaucoma or Ocular Hypertension: A Randomized Phase 3 Study. [PDF]
CureusIntroduction Fixed-dose combinations (FDCs) have the potential in glaucoma management to improve efficacy due to the complementary mechanism of action of the drugs as well as compliance while reducing adverse effects by minimizing exposure to ...
Bhagat P +9 more
europepmc +2 more sources
International Journal of Pharmaceutics, 2019 Eye drops containing hydrophilic drugs are commonly used to reduce intraocular pressure (IOP) in glaucoma patients, but compliance to the treatement is commonly reduced by frequent dosing and eventual systemic side effects.
Giselle Foureaux +2 more
exaly +2 more sources
Intravitreal Bevacizumab Alone Vs Combined With Topical Timolol-Dorzolamide or Dorzolamide for Diabetic Macular Edema: A Systematic Review and Meta-Analysis [PDF]
Clinical OphthalmologyRahaf A Hubayni,1,2 Jumanah Qedair,1,2 Ziad M Bukhari,3 Ali S Alsudais,1,2 Orjwan Salah Badghaish,1,2 Razan Osama Bawazir,1,2 Abdullah S AlQahtani,1– 3 Hashem Almarzouki1– 3 1College of Medicine, King Saud Bin Abdulaziz University for Health Sciences ...
Hubayni RA +7 more
doaj +2 more sources